Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Future Oncology

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

OTOlga TsvetkovaTGTomás Escobar GilGKG Kassir

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates efficacy and safety of datopotamab deruxtecan in EGFR-mutated lung cancer, suggesting a promising new option.

Key Points

  • To assess the efficacy and safety of datopotamab deruxtecan in treating EGFR-mutated non-small cell lung cancer (NSCLC).
  • Pooled analyses from TROPION-Lung01 and TROPION-Lung05 trials
  • Evaluation of Dato-DXd's objective response rate and duration of response compared to docetaxel
  • Monitoring adverse events and assessing safety profile relative to existing therapies.
  • Dato-DXd achieved an objective response rate of ~45%
  • Median duration of response was 6.5 months
  • Lower rates of grade ≥3 adverse events compared to docetaxel.

Cite This Study

Tsvetkova et al. (2026) studied this question.

synapsesocial.com/papers/6a3f68cdaea7db3c1953fb7ahttps://doi.org/10.1080/14796694.2026.2685854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.2024 · 24 citations
  2. 2Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.2024 · 9 citations
  3. 3Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung012024 · 3 citations
  4. 4Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.2025
  5. 5Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study2024 · 222 citations